Patient and learner experience in a new set up of a multidisciplinary dermatology‐rheumatology clinic care model for psoriatic arthritis

Hong, Cassandra; Fang, Sarah; Yeo, Yi-Wei; Koh, Hong-Yi; Lee, Haur Yueh; Low, Andrea Hsiu-Ling; Leung, Ying Ying

doi:10.1111/1756-185x.14359

Cited by 4 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to common pathophysiological mechanisms and complications, PsOs and PsA are collectively grouped under the term psoriatic disease (PsD) and are associated with specific extra-cutaneous/articular manifestations and comorbidities. Collaborative and multidisplinary approaches with dermatologists and rheumatologists have been developed in different countries in order to better diagnose and manage patients with PsD ( 3 ). There is compelling evidence that PsD carries a greater of developing cardiometabolic diseases as compared to the general population ( 4 , 5 ).…”

Section: Introductionmentioning

confidence: 99%

The cardiometabolic conditions of psoriatic disease

2022

View full text Add to dashboard Cite

Psoriasis (PsO) and psoriatic arthritis (PsA), together known as psoriatic disease (PsD), are immune-mediated diseases with a chronic and relapsing course that affect the skin, the joints or both. The pathophysiology of PsO is complex and involves abnormal expression of keratinocytes and infiltration of the skin with dendritic cells, macrophages, neutrophils and T lymphocytes. Around 30% of patients with PsO develop arthritis with axial and/or peripheral manifestations. Both PsO and PsA share similar Th1- and Th17-driven inflammation, with increased production of inflammatory cytokines, including TNFα, IFN-γ, IL-17, IL-22, IL-23 in the skin and the synovial membrane. PsD is associated with a high burden of cardiometabolic diseases such as hypertension, diabetes, dyslipidemia, obesity, metabolic syndrome and cardiovascular (CV) complications as compared to the general population. These comorbidities share common immunopathogenic pathways linked to systemic inflammation, and are associated with the extent and severity of the disease. Morever, they can influence treatment outcomes in PsD. In this short review, we summarize the available evidence on the epidemiology, clinical aspects and mechanisms of cardiometabolic conditions in patients with PsD. We also discuss the impact of targeted treatments such as methotrexate and biological agents on these cardiometabolic conditions.

show abstract

Section: Introductionmentioning

confidence: 99%

The cardiometabolic conditions of psoriatic disease

2022

View full text Add to dashboard Cite

show abstract

The impact of multidisciplinary clinics in dermatology: A review

Antonson,

Thomas,

Borucki

et al. 2024

JAAD Reviews

View full text Add to dashboard Cite

Experience of patients and healthcare practitioners with interdisciplinary care in immune‐mediated inflammatory diseases with skin manifestations: A systematic scoping review

Van den Steen,

De Cock,

Lambert

et al. 2024

Acad Dermatol Venereol

View full text Add to dashboard Cite

Immune‐mediated inflammatory diseases with skin manifestations (skIMIDs) may affect multiple organs. Interdisciplinary care (IC) can overcome the fragmented knowledge used in the management of skIMIDs. In skIMIDs‐care, patient and healthcare practitioner (HCP) satisfaction with IC is unknown. Yet, patient experience influences adherence and medical outcomes. Moreover, HCP experience influences professional satisfaction, perception of care quality and autonomy. Thus, measuring patient and HCP experience can identify areas for improvement in care delivery. The aim of this scoping review was to gather evidence on patient‐ and HCP perceptions on skIMID‐IC and their measurement. We systematically searched on 30 August 2023 PubMed/EMBASE/Cinahl/Web of Science. Eligible studies had to address explicitly experience of IC by patients or HCPs. A conceptional synthesis appraised how experiences were measured and IC was perceived by patients and HCPs. The database search resulted in 21 eligible studies. Fourteen described positive patient and HCP experiences with a specific IC programme. These studies were heterogenous on the levels of IC models, medical conditions, measurement methods and outcomes. Despite that patients and HCPs rated such tailored IC models positively, seven studies on a geographically broader region reported less satisfaction with IC. A conceptual analysis identified domains deemed as important regarding IC: ‘general satisfaction’, ‘patient‐HCP interaction’, ‘information’, ‘functioning of IC’, ‘benefits of IC’. For patients, ‘access to care’ and ‘disease management’ were added. For HCPs ‘illness perception’ was deemed relevant. The heterogeneous way in how IC experience is captured hinders strong conclusions, which mandates the development of standardized analysis tools. Experience with IC in skIMIDs strongly depends on the context of the provided IC and patient experience seems to be better in local IC programmes than systems rolled out in larger geographical regions. Future need is to develop a core IC outcome set including medical outcomes, process indicators, financial indicators, plus patient and HCP care experience measures.

show abstract

Patient and learner experience in a new set up of a multidisciplinary dermatology‐rheumatology clinic care model for psoriatic arthritis

Cited by 4 publications

References 20 publications

The cardiometabolic conditions of psoriatic disease

The cardiometabolic conditions of psoriatic disease

The impact of multidisciplinary clinics in dermatology: A review

Experience of patients and healthcare practitioners with interdisciplinary care in immune‐mediated inflammatory diseases with skin manifestations: A systematic scoping review

Contact Info

Product

Resources

About